Abstract

Automated, Sensitive Microfluidic Device for CTC Capturing and Characterization

Grant Howes, VP, Commercial Operations, Celsee Diagnostics

The Celsee Diagnostics’ novel microfluidic technology captures and characterizes CTCs from metastatic cancer patients’ whole blood samples based on size and deformability. The design enables downstream characterization of CTCs, including IHC, FISH, PCR and NGS.

This presentation will overview the technology, demonstrate the 85% capture efficiency and discuss the use of the Celsee PREP100 to enrich and retrieve CTCs for downstream applications. The Celsee PREP100 device uses a microfluidic chip, which has approximately 56,400 individual cell capturing wells. Each well ensures that smaller blood cells, such as red blood cells and most leukocytes, escape while larger CTCs are captured.

Downstream analysis of the captured CTCs using immuno-staining, FISH assays, RTPCR and NGS will be highlighted.